Abstract:Abstract Introduction Metabolic perturbations and sleep disruptions are a cause and consequence of Alzheimer’s disease pathophysiology. A bidirectional relationship exists where impairments in sleep and metabolism contribute to the development of Alzheimer’s disease while the presence of Alzheimer’s disease pathology leads to decreased cerebral metabolism, peripheral glucose intolerance, and disrupted sleep. While the effects of type 2 diabetes (T2D) and Alzheimer’s disease on sleep have been explored separately, no previous studies have examined the effect of acute glycemic variability, a defining feature of T2D, on sleep in the context of Alzheimer’s disease. The goal of this study is to determine how glycemic variability drives sleep disruptions by modifying the relationship between cerebral glucose metabolism and neuronal activity. Methods Biosensors are implanted bilaterally into the hippocampus of APP/PS1, a model of amyloid-beta (Aβ) overexpression, and P301S, a model of tau deposition and neurodegeneration, mice to measure ISF glucose and lactate, markers of cerebral metabolism and neuronal activity, respectively. Simultaneous cortical EEG/EMG recordings are used for sleep/wake scoring and analysis. Results Glycemic fluctuations cause a decoupling of the typical relationships between cerebral metabolism and neuronal activity, while also increasing arousal in 3-month-old, wildtype mice. The presence of AD-like pathology results in a similar, albeit muted cerebral metabolic response to peripheral glycemic variability, but a diminished effect on wakefulness, likely due to age- and pathology-dependent increases in overall time spent awake. Conversely, in aged, P301S mice, cerebral metabolic responsiveness is lost and a ceiling effect on wakefulness emerges, suggesting differential effects on sleep with tau accumulation. Moreover, aged mice show progressive disruptions to overall sleep quality and quantity, highlighting the synergism existing between AD-like pathology and glucose intolerance in sleep dysfunction. Lactate seems to be a common driver of disruption in this synergistic cycle. Conclusion This study represents a novel approach to defining the dynamic interplay between risk factors for AD and T2D and suggests a feedforward loop of disease progression where disrupted sleep can alter the relationship between neuronal activity, metabolism, and pathology. Support NIH/NIA 1K01AG050719. Harold and Mary Eagle Fund for Alzheimer’s Research New Vision Award through Donors Cure Foundation

Metabolic Profiling of Suprachiasmatic Nucleus Reveals Multifaceted Effects in an Alzheimer's Disease Mouse Model

Spatially conserved pathoprotein profiling in the human suprachiasmatic nucleus in progressive Alzheimer disease stages

Degeneration and energy shortage in the suprachiasmatic nucleus underlies the circadian rhythm disturbance in ApoE −/− mice: implications for Alzheimer’s disease

Dysregulated clock gene expression and abnormal diurnal regulation of hippocampal inhibitory transmission and spatial memory in amyloid precursor protein transgenic mice

Impaired clock gene expression and abnormal diurnal regulation of hippocampal inhibitory transmission and spatial memory in a mouse model of Alzheimer’s disease

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer’s disease

CIRCADIAN CLOCK DISRUPTION: SEX-SPECIFIC EFFECTS ON METABOLISM & COGNITION IN AN ALZHEIMER’S MODEL

Spatial transcriptomics identifies disrupted circadian gene expression in a mouse model of Alzheimer’s disease

Global Metabolic Shifts in Age and Alzheimer's Disease Mouse Brains Pivot at NAD+/NADH Redox Sites

Hippocampal Metabolomics Using Ultrahigh-Resolution Mass Spectrometry Reveals Neuroinflammation from Alzheimer’s Disease in CRND8 Mice

Altered sleep behavior strengthens face validity in the ArcAβ mouse model for Alzheimer's disease

Investigating metabolic dysregulation in serum of triple transgenic Alzheimer's disease male mice: implications for pathogenesis and potential biomarkers

Effects of the Clock Modulator Nobiletin on Circadian Rhythms and Pathophysiology in Female Mice of an Alzheimer’s Disease Model

Hypothalamic and hippocampal transcriptome changes in AppNL-G-F mice as a function of metabolic and inflammatory dysfunction

Sleep and diurnal rest-activity rhythm disturbances in a mouse model of Alzheimer's disease

Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology.

0415 Metabolic Dysfunction and Sleep Disruption in Models of Alzheimer’s Disease

Circadian rhythmicity of amyloid-beta-related molecules is disrupted in the choroid plexus of a female Alzheimer's disease mouse model

Metabolic and vascular imaging markers for investigating Alzheimer's disease complicated by sleep fragmentation in mice

Circadian and sleep phenotypes in a mouse model of Alzheimer's disease characterized by intracellular accumulation of amyloid β oligomers